What is the present valuation and projected CAGR of the cancer biopsy market?
The cancer biopsy market size has grown rapidly in recent years. It will grow from $25.08 $ billion in 2024 to $28.52 $ billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to increasing awareness of breast cancer liquid biopsy procedures, rising awareness of inherited oncology disorders and genetic testing, increasing adoption of liquid biopsies, increasing demand of for minimally invasive biopsy treatments, increasing demand for tissue biopsies.
The cancer biopsy market size is expected to see rapid growth in the next few years. It will grow to $47.2 $ billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to an increase in the number of patients, the growing elderly population, the growing number of patients suspected of having breast cancer, the rise in cancer cases, an increase in the diagnosis and biopsies testing, increase in the number of patients. Major trends in the forecast period include technological advancements, artificial intelligence and machine learning, integration of multi-omics, product innovations, and point-of-care biopsy devices.
Get Your Free Sample of The Global Cancer Biopsy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19355&type=smp
What key drivers have fueled the cancer biopsy market’s development over the years?
The increasing prevalence of cancer is expected to propel the growth of the cancer biopsy market going forward. Cancer is a complex group of diseases characterized by the abnormal growth and spread of cells. The increasing prevalence of cancer is due to several factors, such as lifestyle changes and urbanization, environmental pollution, tobacco and alcohol consumption, healthcare access, and awareness. A cancer biopsy is used to diagnose and assess cancer type, stage, and spread by extracting and analyzing tissue or cells from a suspicious area. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, in the United States there were 1,958,310 new cancer cases and 609,820 cancer deaths. Furthermore, in May 2021, according to the National Library of Medicine, a US-based medicine library, the global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a large number of deaths. Therefore, the increasing prevalence of cancer drives the cancer biopsy market.
What is the segmentation for the cancer biopsy market?
The cancer biopsymarket covered in this report is segmented –
1) By Type: Tissue Biopsies, Liquid Biopsies, Other Types
2) By Application: Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Other Applications
3) By End User: Hospitals, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Tissue Biopsies: Core Needle Biopsies, Fine Needle Aspiration (FNA) Biopsies, Incisional Biopsies, Excisional Biopsies
2) By Liquid Biopsies: Circulating Tumor Cell (CTC) Analysis, Circulating Tumor DNA (ctDNA) Testing, Plasma Biomarker Testing
3) By Other Types: Bone Biopsies, Endoscopic Biopsies, Brush Biopsies, Skin Biopsies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cancer-biopsy-global-market-report
Who are the most influential companies in the cancer biopsy market?
Major companies operating in the cancer biopsy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Roche Diagnostics GmbH, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., Guardant Health Inc., Veracyte Inc., GRAIL Inc., Freenome Holdings Inc., Biodesix Inc., Chronix Biomedical Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Oncimmune Holdings plc, Exosome Diagnostics Inc., Epigenomics AG, Genesystems Inc., Lucence Diagnostics Pte. Ltd., ANGLE plc
What are the top industry trends projected to impact the cancer biopsy market?
Major companies operating in the cancer biopsy market are developing liquid biopsy techniques to enable non-invasive, early detection and monitoring of cancer, improve patient outcomes, and allow for more personalized treatment approaches. Liquid biopsy is an advanced, non-invasive diagnostic technique that detects and analyzes genetic material from a blood sample, such as circulating tumor DNA (ctDNA), RNA, exosomes, and other biomarkers. For instance, in May 2023, Labcorp, a US-based company specializing in the manufacturing of cancer biopsies, launched Labcorp Plasma Focus, a plasma-focused liquid biopsy to detect cancer-related biomarkers. The Plasma Focus test analyzes circulating cell-free DNA (cfDNA) released from tumor cells into the bloodstream and can construct a genomic profile of the patient’s tumor, identifying mutations across 33 genes associated with various cancers, including non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, and melanoma.
What are the major regional insights for the cancer biopsy market, and which region holds the top position?
North America was the largest region in the cancer biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cancer Biopsy Market Report 2025 Offer?
The cancer biopsy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A cancer biopsy is a medical procedure that involves the removal of a small sample of tissue or cells from a suspicious area of the body to determine the presence of cancer or other conditions. This procedure is essential for diagnosing cancer, as imaging tests such as computed tomography (CT) scans or magnetic resonance imaging (MRI) cannot definitively differentiate between cancerous and non-cancerous cells.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19355
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
